AIDS WEEKLY Plus - December 2002Important note: Information in this article was accurate in December 2002. The state of the art may have changed since the publication date.
Click here to return to AIDS WEEKLY PLUS main menu

HIV/AIDS Complications: Mucosal plasma cell diversity remains adequate after infection

AIDSWEEKLY Plus; Monday, December 16, 2002
Michael Greer, Senior Medical Writer


NewsRx -- Researchers in the United States have provided new insight into the efficacy of mucosal immune activity during HIV infection.

"Impaired development of local Ab [antibody] responses may predispose HIV-1-infected patients to an increased rate, severity, and duration of mucosal infections," according to Ronald W. Scamurra and colleagues at the University of Minnesota and the Veterans Affairs Medical Center in Minneapolis and the University of California at San Diego in La Jolla.

However, Scamurra and coauthors found only minor degradation of mucosal plasma cell repertoire in HIV patients.

The researchers evaluated the diversity of immunoglobulin (Ig)-producing cells in HIV patients' intestinal effector compartments. Seropositive patients were significantly deficient in colon, lumen, and duodenum IgA-producing cells compared with healthy controls, according to the report.

However, the low numbers of IgA-producing cells in HIV patients were mitigated by elevated levels of cells producing IgG or IgM, study data showed. Antibody VH gene expression was comparably diverse in most HIV patients and controls.

Important to note is that the VH gene repertoire in seropositive patients included normal amounts of VH3 genes thought to bind the HIV coat protein gp120 (Mucosal plasma cell repertoire during HIV-1 infection. J Immunol 2002 Oct 1;169(7):4008-16.

"These data suggest that HIV-1-infected patients use functional regulatory mechanisms to provide sufficient VH diversity and effective induction and differentiation of mucosal B cells," Scamurra and colleagues concluded.

The corresponding author for this report is Edward N. Janoff, University of Minnesota School of Medicine, Mucosal and Vaccine Research Center, Infectious Disease Sect. 111F, Veterans Affairs Medical Center, 1 Veterans Dr., Minneapolis, MN 55417, USA. E-mail: janof001@tc.umn.edu.

Key points reported in this study include:

This article was prepared by AIDS Weekly editors from staff and other reports.

021216
AW021210


Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.